Invesco Biotechnology & Genome ETF
PBE
74 hedge funds and large institutions have $93.2M invested in Invesco Biotechnology & Genome ETF in 2018 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 12 closing their positions.
73% more capital invested
Capital invested by funds: $53.9M → $93.2M (+$39.3M)
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
7.39% more ownership
Funds ownership: 21.67% → 29.06% (+7.4%)
1% more funds holding
Funds holding: 73 → 74 (+1)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Arlington Capital Management
Arlington Heights,
Illinois
|
+$32.1M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.35M |
| 3 |
YIA
YHB Investment Advisors
West Hartford,
Connecticut
|
+$1.25M |
| 4 |
Wells Fargo
San Francisco,
California
|
+$657K |
| 5 |
Morgan Stanley
New York
|
+$548K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$730K |
| 2 |
Jane Street
New York
|
-$645K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$445K |
| 4 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
-$353K |
| 5 |
TAM
Trillium Asset Management
Boston,
Massachusetts
|
-$215K |
PBE Hedge Fund Activity: Q3 2018 in Review
74 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q3 2018, worth a combined $93.2M — up 73% from $53.9M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PBE positions and 12 closed out — a net gain of 2 holders — while 15 added to existing stakes and 16 trimmed.
The largest buyer was Arlington Capital Management, opening a new position worth an estimated $32.1M. The largest seller was Citadel Advisors, exiting entirely with an estimated $730K sold.
- 74 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q3 2018, up from 73 in Q2 2018.
- Funds reported $93.2M of Invesco Biotechnology & Genome ETF stock for Q3 2018, up 73% quarter-over-quarter.
- 14 funds opened new Invesco Biotechnology & Genome ETF positions in Q3 2018 and 12 closed out, a net change of +2 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q3 2018 was Arlington Capital Management, an estimated $32.1M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q3 2018 was Citadel Advisors, an estimated $730K sold.
Based on aggregated 13F filings for Q3 2018.